Elanco Animal Health (NYSE:ELAN – Get Free Report) was downgraded by investment analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Briefing.com reports. They currently have a $24.00 price target on the stock. Jefferies Financial Group’s price objective would indicate a potential upside of 2.13% from the company’s previous close.
Several other research analysts also recently issued reports on ELAN. UBS Group lifted their price target on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Morgan Stanley increased their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. The Goldman Sachs Group started coverage on shares of Elanco Animal Health in a research report on Friday. They set a “buy” rating and a $32.00 target price for the company. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Elanco Animal Health has an average rating of “Moderate Buy” and an average price target of $29.42.
View Our Latest Analysis on Elanco Animal Health
Elanco Animal Health Stock Performance
Shares of ELAN stock opened at $23.50 on Tuesday. The stock has a fifty day moving average price of $23.25 and a 200 day moving average price of $23.58. The stock has a market cap of $11.74 billion, a PE ratio of -57.31, a P/E/G ratio of 1.68 and a beta of 1.70. Elanco Animal Health has a 1 year low of $19.40 and a 1 year high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. Elanco Animal Health’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Sell-side analysts forecast that Elanco Animal Health will post 1.13 earnings per share for the current fiscal year.
Insider Activity at Elanco Animal Health
In related news, Director Paul Herendeen purchased 10,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $23.68 per share, with a total value of $236,800.00. Following the completion of the acquisition, the director directly owned 111,687 shares in the company, valued at $2,644,748.16. The trade was a 9.83% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Harrington purchased 5,000 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was bought at an average cost of $21.82 per share, with a total value of $109,100.00. Following the completion of the acquisition, the director owned 131,451 shares of the company’s stock, valued at approximately $2,868,260.82. The trade was a 3.95% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 63,198 shares of company stock valued at $1,473,109 in the last ninety days. 1.14% of the stock is owned by insiders.
Institutional Investors Weigh In On Elanco Animal Health
Hedge funds have recently modified their holdings of the company. Anchor Investment Management LLC purchased a new position in shares of Elanco Animal Health during the second quarter valued at approximately $29,000. Integrated Wealth Concepts LLC acquired a new stake in Elanco Animal Health during the second quarter worth approximately $35,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Elanco Animal Health during the second quarter worth approximately $38,000. Bessemer Group Inc. grew its stake in Elanco Animal Health by 33.2% in the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after acquiring an additional 525 shares during the period. Finally, Farther Finance Advisors LLC grew its stake in Elanco Animal Health by 12.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,184 shares of the company’s stock worth $94,000 after acquiring an additional 464 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.
Elanco Animal Health Company Profile
Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.
The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.
Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.
Featured Stories
- Five stocks we like better than Elanco Animal Health
- Amprius Technologies’ Next Big Rally Could Be Taking Shape
- 4 Stocks With Demand So Sticky That the AI Sell-Off Barely Touched Them at All
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
